Munveer Thind
Cardiovascular Disease · Danville, PANPI 1235515313
Payments from drug & device makers
What this record shows
This record is dominated by grants: $38,689 of the $56,803 with a category attached, or 68.1%. 14 manufacturers reported payments, led by Johnson & Johnson at 41.7% of the total. Reporting peaked in 2021 at $24,108 and has fallen 76.2% since, to $5,747 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $294.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$24K
- Boston Scientific$18K
- Medtronic$8K
- Biotronik Inc.$3K
- Abbott$3K
- Biosense Webster, Inc.$1K
- plus $583 from 8 others
Across 12 payments — averaging $700.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$8K
What the payments were for
- Grants$38,68968%
- Travel & lodging$7,99014%
- Food & beverage$8,90316%
- Education$1,2212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 2 | $23,700 |
| Boston Scientific | 12 | $17,616 |
| Medtronic(2 entities) | 82 | $8,120 |
| Biotronik Inc. | 44 | $2,764 |
| Abbott | 21 | $2,642 |
| Biosense Webster, Inc. | 13 | $1,378 |
| AstraZeneca | 6 | $170 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Novartis | 4 | $74 |
| Boehringer Ingelheim | 3 | $66 |
| Pfizer | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Terumo Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$1,434
- Carto 3$1,181
- EVERA MRI XT DR SURESCAN$1,175
- WATCHMAN Access System$924
- CROME DR MRI SURESCAN$719
- Micra$561
- HeartMate 3 Left Ventricular Assist Device$201
- ENSITE PRECISION$177
- COBALT DR MRI SURESCAN$159
- ENSITE$144
- AURORA EV-ICD MRI SURESCAN$129
- ELIQUIS$121
How this compares
$56,803 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 12 | $1,026 |
| Omeprazole | 31 | $213 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Danville
- Dominik BeerDanville$87K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.